WASHINGTON, Nov. 5 /PRNewswire-USNewswire/ -- For the next two weeks, the "Help is Here Express" national bus tour will be in wildfire-ravaged areas of Southern California, attempting to help uninsured and under-insured victims access the medicines they need. The first stop will be from 10 a.m. until 2 p.m. today at St. Peter's Catholic Community Church in Fallbrook, CA.
This marks the seventh time the Partnership for Prescription Assistance (PPA), a nationwide effort sponsored by America's pharmaceutical research companies, has been to California. The PPA is a national clearinghouse and a single point of access to more than 475 patient assistance programs -- including nearly 200 sponsored by pharmaceutical companies -- which provide free or nearly free medicines to eligible patients in need. Patients can find out in 10 to 15 minutes free of charge if they may qualify for assistance. So far, the PPA has helped more than 250,000 Californians in a little over two years. Nationwide, it has helped more than 4.3 million patients.
In addition to help from the PPA, America's pharmaceutical research companies have already contributed millions of dollars in cash and products to California's fire victims in an effort spearheaded by three California-based companies -- Amgen Inc., Amylin Pharmaceuticals, Inc., and Valeant Pharmaceuticals International. Other companies making contributions include Abbott, AstraZeneca LP, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Novo Nordisk Inc., Pfizer Inc, Hoffman-LaRoche Inc, Schering-Plough Corporation, Takeda Pharmaceuticals North America, Inc., Wyeth, Otsuka America, Inc. and Bayer HealthCare Pharmaceuticals. The donations have been made to a wide range of organizations, including the American Red Cross, AmeriCares, Project Hope, BIOCOM's Fire Relief Biotech Recovery Response Fund, the Southern California Wildfire Relief Fund, the After-the-Fires Fund and Direct Relief International.
The na
'/>"/>
| SOURCE Pharmaceutical Research Manufacturers of America Copyright©2007 PR Newswire. All rights reserved |